kleinishere
Pi+some additions here. Have not used it enough to have a strong opinion, however, I’ve seen it mentioned here.
Run your own Asterisk server with special #0 that the kids can dial to listen to children’s podcasts, etc., it can be very entertaining.
https://www.epa.gov/greenchemistry/green-chemistry-challenge...
How has the translation quality changed / improved since this Show HN a couple years back? https://news.ycombinator.com/item?id=39177467
For languages not using the Roman alphabet, is it required that the user know the characters already? After registering but before starting a trial, I wasn’t clear on this.
Some comparison of who should choose this over Duolingo and why (ie features) could be useful.
Does your daily log link to other parts of one org file, or other org files?
I’ve asked LLMs their opinions. But curious for yours!
Also thinking about trying denote. The filenames begin with dates, then use tags/keywords to keep the thread on recurring topics.
For others who stumble upon this, another good free site without too many ads:
Similarly published by OpenAI: https://status.openai.com/
30 day comparisons as of writing:
99.61% for Claude.ai 99.22% for ChatGPT
99.92% for Claude APIs 99.25% for OpenAI APIs
Obviously not apples to apples and somewhat up to discretion of what triggers an impact. We’re clearly not at 99.99% yet.
I used Doom for a couple months.
Then started considering a vanilla eMacs. I started taking notes on packages I found highly recommended and interesting.
Then I found this. And the author has done all that work and then made it into a “let me walk through a config” including a lot of the most recommended packages and sensible configs.
Gives you the lesson of building a config, knowing what’s in your config, and then being fluent in changing it.
He also has more notes on his blog about the packages + more : https://www.jamescherti.com/essential-emacs-packages/
And I now feel comfortable making changes myself.
I looked on Amazon after another receipt printer post on HN but couldn’t find anything that provided confidence in the BPA characterization. ULINE is quantities are absurd for personal use. Imagine their most be a decent alternative but never see any named.
I also purchased my first iOS app upon recommendation from other emacs users - the author’s app, Journelly. A simple portable place to save down links or notes and export out as org files (as one option; apparently markdown is on the way). https://xenodium.com/journelly-for-ios
No affiliation to Xenodium. I’ve just been diving into emacs this year and love seeing his contributions.
Novo Nordisk purchased Corvidia Therapeutics in 2020 [1] for their IL-6 antibody and will read out the first of three Phase 3's in 2026 [2]. Their programs, however, are focused on individuals with higher risk factors like chronic kidney disease (2026 topline), a couple kinds of heart failure (2027), and a prior myocardial infarction (heart attack; 2027). These trials notably are on top of "standard of care" existing therapies, so they're looking for additional benefit beyond what is commonly sought, like LDL reduction (highlighted in other comments).
Novartis recently announced an intended acquisition of Tourmaline Bio for their IL-6 antibody [3]. So attention to the biological target is heating up.
Another target mentioned in the comments is Lp(a). Genetic studies suggest a heightened risk of cardiovascular disease. Therapeutics aimed at reducing Lp(a) levels are being explored separate from IL-6 for a similar end goal of avoiding cardiovascular events (i.e. heart attacks, death).
Novartis will read out a Phase 3 of an Lp(a) reducing therapeutic in the first half of 2026 [4]. Amgen will likely read out theirs likely sometime thereafter [5]. These have been a long time coming: Amgen in-licensed their asset from Arrowhead in 2016 [6], Novartis in-licensed their asset from Ionis/Akcea in 2017 [7].
If any of these work, there's a chance that they'd be explored in patients with less pronounced risk than the original studies in these Phase 3's. Amgen has already announced an intent to explore their Lp(a) drug in a Phase 3 with participants with elevated Lp(a) at "high risk" for a first cardiovascular event in 2H25/1H26.
[1] https://ml-eu.globenewswire.com/Resource/Download/e7e162e5-a... [2] Page 113 - https://cdn.ipaper.io/iPaper/Files/ffd0326c-1fa6-41e5-a82d-0... Page 225 - https://investor.novonordisk.com/q2presentation2025/?page=22... [3] https://ir.tourmalinebio.com/news-releases/news-release-deta... [4] https://ir.ionis.com/static-files/66c5e90a-3651-480d-a596-1c..., https://clinicaltrials.gov/study/NCT04023552 [5] https://clinicaltrials.gov/study/NCT05581303?rank=1, Page 15 - https://investors.amgen.com/static-files/27fcb898-9cee-48db-... [6] https://www.amgen.com/newsroom/press-releases/2016/09/amgen-... [7] https://ir.ionis.com/news-releases/news-release-details/ioni...
https://www.facebook.com/share/p/19UdGkBYwr/?mibextid=wwXIfr
Also discussed on Reddit.